Terlipressin acetate + Serelaxin (RLX030)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Compensated Cirrhosis and Portal Hypertension
Conditions
Compensated Cirrhosis and Portal Hypertension
Trial Timeline
Apr 1, 2013 → Dec 1, 2014
NCT ID
NCT01640964About Terlipressin acetate + Serelaxin (RLX030)
Terlipressin acetate + Serelaxin (RLX030) is a phase 2 stage product being developed by Novartis for Compensated Cirrhosis and Portal Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01640964. Target conditions include Compensated Cirrhosis and Portal Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01640964 | Phase 2 | Completed |
Competing Products
9 competing products in Compensated Cirrhosis and Portal Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| Mesenchymal Stem Cell | Rohto Pharmaceutical | Pre-clinical | 23 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1/2 | 41 |
| Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV | Merck | Approved | 85 |
| telbivudine/LDT600 | Novartis | Approved | 85 |
| Aliskiren + Placebo | Novartis | Phase 3 | 77 |
| Telbivudine/LDT600A | Novartis | Approved | 85 |
| BMS-986259 | Bristol Myers Squibb | Phase 2 | 51 |
| Albutein 20% | Grifols | Phase 3 | 74 |